A Phase II, Placebo-Controlled, Multicenter, Dynamic Randomized, Double Blind Trial of RC18, a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Inadequate Response of TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Methotrexate (Primary) ; RC 18 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors RemeGen
- 31 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 31 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated